Millions of Americans are battling Parkinson’s disease with limited treatment options.
The medical establishment has been slow to deliver real solutions.
But Big Pharma just made one breakthrough announcement that could change everything for Parkinson’s patients.
FDA accepts groundbreaking Parkinson’s treatment for review
Mitsubishi Tanabe Pharma America delivered some much-needed hope to the Parkinson’s community this week.
The company announced that the U.S. Food and Drug Administration has accepted their New Drug Application resubmission for ND0612, an investigational treatment for motor fluctuations in Parkinson’s disease patients.
This represents a second chance for a treatment that has already undergone extensive review by federal regulators.
This isn’t just another pill that patients have to remember to take multiple times a day.
ND0612 represents a completely different approach to treating one of the most debilitating aspects of Parkinson’s disease.
The treatment works as a continuous, 24-hour subcutaneous infusion of liquid levodopa and carbidopa delivered directly under the skin.
For patients who experience the unpredictable motor fluctuations that make daily life a constant struggle, this could be a game-changer.
“The FDA’s acceptance of the NDA for ND0612 is a critical milestone that brings us one step closer to delivering a potential therapeutic option for people with Parkinson’s disease who continue to experience disruptive motor fluctuations,” said Yasutoshi Kawakami, President of Mitsubishi Tanabe Pharma America.
The FDA has set a target action date for the fourth quarter of 2025, meaning patients could see this treatment available before the year ends.
Why this matters for patients and families
Anyone who has watched a loved one battle Parkinson’s disease knows the cruel reality of motor fluctuations.
One moment, a patient might be moving normally and talking clearly.
The next, they could be frozen in place, unable to walk or speak properly.
These unpredictable episodes rob patients of their independence and dignity.
Current treatments require patients to take multiple doses of medication throughout the day, trying to time everything perfectly to maintain consistent symptom control.
But the human body doesn’t work like clockwork, and neither do traditional Parkinson’s medications.
ND0612’s continuous delivery system could eliminate the peaks and valleys that make life so unpredictable for Parkinson’s patients.
The treatment is backed by data from a pivotal Phase 3 clinical trial called BouNDless, which evaluated both effectiveness and safety in patients experiencing motor fluctuations.
Additional long-term safety data comes from an ongoing Phase 2b study called BeyoND, with some participants now in their eighth year of follow-up.
The companies behind the breakthrough
This development comes from NeuroDerm, Ltd., an Israeli subsidiary of Mitsubishi Tanabe Pharma Corporation that led the clinical development of ND0612.
Mitsubishi Tanabe Pharma Corporation has an impressive pedigree in the pharmaceutical world, having been founded in 1678 and focusing on ethical pharmaceuticals for centuries.
The company has set an ambitious mission of “Creating hope for all facing illness” and is working specifically in disease areas including central nervous system disorders like Parkinson’s.
If the FDA approves ND0612, Mitsubishi Tanabe Pharma America will handle commercialization in the United States.
A new era of precision medicine
This development represents more than just another treatment option.
It signals a shift toward what the pharmaceutical industry calls “precision medicine” – providing drugs with high treatment satisfaction by identifying patient populations with the highest potential for efficacy and safety.
The company is also working on what they call “around the pill solutions” that address specific patient concerns beyond just the medication itself.
This includes focusing on prevention of diseases, pre-symptomatic care, prevention of disease progression, and improving long-term outcomes.
For Parkinson’s patients and their families, ND0612 could represent the kind of breakthrough they’ve been waiting for.
The continuous delivery system could provide the steady symptom control that has been so elusive with traditional oral medications.
Hope on the horizon
The acceptance of this New Drug Application represents years of research and development finally reaching a critical milestone.
While patients will still need to wait for the FDA’s final decision later this year, the acceptance of the application is a strong signal that regulators see promise in this innovative approach.
For Parkinson’s patients and their families across America, ND0612 could represent the kind of breakthrough they’ve been waiting for.
The fourth quarter of 2025 can’t come soon enough for families who have been waiting for a treatment that could give them back some control over their daily lives.
